Summary of Study ST004262
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002689. The data can be accessed directly via it's Project DOI: 10.21228/M82R9H This work is supported by NIH grant, U2C- DK119886. See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST004262 |
| Study Title | The lipidome of drug-resistant glioblastoma persister cells. |
| Study Summary | This study aimed to determine mechanisms through which glioblastoma stem cells acquire a drug-resistant phenotype. A small proportion of glioblastoma stem cells survive chemotherapy and radiotherapy, creating a drug-resistant persister cell population that resumes proliferation after the cessation of drug treatment. The specific experiment profiled the lipidome of glioblastoma stem cells that survive treatment with the anti-microtubule agent CMPD1. Glioblastoma stem cell line RKI1 was treated for 14 days with 25 micromolar CMPD1 to generate drug-resistant persister cells, replacing the cell culture medium every 3 days (n = 3). At day 14 of treatment, the CMPD1-treated cells were collected for lipid extraction and lipidomic analysis. The drug-resistant persister cells were compared to control cells grown in RKI1 growth medium and collected prior to drug-treatment (n = 3). The drug-resistant persister cells displayed significantly decreased levels of ceramide and cholesterol, and increased sphingomyelin and diacylgylcerol, indicative of membrane remodelling that may allow the cells to survive chemotherapy. Further investigation indicated that the reduced cholesterol content provides a point of metabolic vulnerability to eliminate the drug resistant persister cells. |
| Institute | University of Sydney |
| Department | School of Medical Sciences |
| Last Name | Don |
| First Name | Anthony |
| Address | Office 3210, D17 Charles Perkins Centre, Camperdown, NSW, 2006 |
| anthony.don@sydney.edu.au | |
| Phone | +612 8627 5578 |
| Submit Date | 2025-09-29 |
| Num Groups | 2 |
| Total Subjects | 6 |
| Study Comments | Control and drug-treated RKI1 glioblastoma cells |
| Publications | Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-10-10 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU004415 |
| Subject Type: | Cultured cells |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Cell Biosource Or Supplier: | QIMR Berghofer Institute |
| Cell Strain Details: | Patient-derived glioblastoma stem cell line RKI1 |
